Physician profile
Leonard C Giunta
NPI 1073657334
$3,242.34
in general payments reported to CMS, 2019-2025
31 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $722 · 2020: $704 · 2021: $648 · 2022: $633 · 2023: $326 · 2024: $85.90 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $537.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $536.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $511.67 | 2019-2025 | Farxiga |
| Abbvie INC. | $420.35 | 2021-2024 | |
| Novo Nordisk INC | $371.15 | 2019-2023 | |
| Pfizer INC. | $254.77 | 2019-2023 | |
| Astellas Pharma US INC | $247.49 | 2019-2023 | Myrbetriq, Veozah |
| Lilly USA, LLC | $226.52 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Boehringer Ingelheim Pharmaceuticals, INC. | $130.14 | 2019-2022 | |
| Allergan, INC. | $119.16 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.76 | 2021-2025 | |
| Amgen INC. | $89.32 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $85.38 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $76.47 | 2020-2023 | Seglentis |
| Abiomed | $70.20 | 2024-2025 | Impella |
| Merck Sharp & Dohme LLC | $61.94 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $44.57 | 2019 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $43.93 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.87 | 2022 | |
| Amarin Pharma, INC. | $38.69 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $37.18 | 2024-2025 | Camzyos, Eliquis |
| Mylan Specialty L.P. | $37.10 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $30.03 | 2021 | |
| Urovant Sciences INC | $27.53 | 2022 | |
| Eisai INC. | $24.20 | 2020 | |
| Biogen, INC. | $21.74 | 2021 | |
| Celgene Corporation | $21.23 | 2019 | |
| Scilex Pharmaceuticals INC. | $17.05 | 2019 | |
| Linus Health, INC. | $17.04 | 2023 | |
| Sumitomo Pharma America, INC. | $16.43 | 2023 | Gemtesa |
| Idorsia Pharmaceuticals US INC | $16.04 | 2022 | |
| Alfasigma USA, INC. | $15.90 | 2021 | |
| Sanofi Pasteur INC. | $15.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonard Giunta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.